Alkermes gained an exclusivity extension for Lybalvi, which RBC expects to help counter the impact of an alixorexton pricing change. With no size given for either, the report does not show a clear change in Alkermes' outlook.
The extension could let Alkermes keep exclusive sales rights for Lybalvi longer. RBC says this should help counter the effect of a pricing change for alixorexton. The report gives no sizes for either change, so it does not show which matters more.
Follow Alkermes (ALKS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALKS